Storia in 8 fonti

Post-Hoc Live: Marty Makary's FDA downfall and legacy

Endpoints News and Financial Times journalists discuss the downfall of FDA Commissioner Marty Makary, live in New York at the FT's biotech and pharma summit.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 mesi fa

Post-Hoc Live: Marty Makary's FDA downfall and legacy

Endpoints News and Financial Times journalists discuss the downfall of FDA Commissioner Marty Makary, live in New York at the FT's biotech and pharma summit.

originale

Timeline cronologica

martedì 12 maggio 2026·statnews.com
Makary departs FDA amid turmoil as Diamantas, agency's top food official, steps in
Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.
martedì 12 maggio 2026·axios.com
Marty Makary out as FDA chief
His tenure was marked by organizational upheaval, controversies over drug approvals and tensions with the White House.

Post-Hoc Live: Marty Makary's FDA downfall and legacy

Confronto fonti

Post-Hoc Live: Marty Makary's FDA downfall and legacy

Timeline cronologica

Makary departs FDA amid turmoil as Diamantas, agency's top food official, steps in

Marty Makary out as FDA chief

Marty Makary’s Turbulent Tenure at FDA Comes to an End

Why Marty Makary was the worst FDA commissioner in 25 years

Marty Makary out as FDA chief

Makary’s time atop FDA over, Diamantas named acting commissioner

After Makary departure, CDER chief Tracy Beth Høeg likely headed out at FDA: report

Makary’s time atop FDA over, Diamantas named acting commissioner

Why Marty Makary was the worst FDA commissioner in 25 years

Post-Hoc: What brought down the FDA commissioner

Opinion | A desperately needed reset at the FDA

Marty Makary’s Turbulent Tenure at FDA Comes to an End

Opinion | Here's How FDA Employees Learned Their Boss Was Really Gone

Post-Hoc Live: Marty Makary's FDA downfall and legacy

After Makary departure, CDER chief Tracy Beth Høeg likely headed out at FDA: report

Makary resigns; Biogen reports Alzheimer’s data; and more